As of December 31 cash and cash equivalents stood at $28.6 million, up $11.6 million on March 31, 2009 "Based on this strong performance, we are raising revenue guidance for fiscal 2010," said John Kilcoyne, Chairman and CEO of Micrus Endovascular Corporation, "We continue to grow our top line while effectively managing expenses, resulting in our fourth consecutive quarter of profitability and positive cash flow from operations." For the nine months ended December 31, 2009, total neurovascular revenues were $65.5 million, Gross margin was 76%, and net income was $9.2 million, or $0.56 per diluted share. Micrus Endovascular now expects total revenues in fiscal 2010 to be in the range of $87 million to $89 million, up from prior guidance of $84 million to $87 million.